Genpact and Bayer to Co-innovate to Leverage Artificial Intelligence Capabilities for Patient Safety

Genpact a professional services firm focused on delivering digital transformation, announced it has signed a multi-year agreement with Bayer, under which Genpact’s Pharmacovigilance Artificial Intelligence (PVAI) suite of capabilities will be applied to Bayer’s existing pharmacovigilance database and IT systems.

“We believe the ability to apply advanced AI technologies, with significant process and domain expertise, will usher in a whole new era of pharmacovigilance by serving as a single machine learning system that can be utilized across the industry by life sciences companies, healthcare providers, and regulators,” said Balkrishan ‘BK’ Kalra, business leader, Life Sciences and Healthcare, Genpact. “We expect safety issues can be identified more rapidly, and resources can be freed up to focus on advanced and effective risk minimization measures. We are thrilled to be working with Bayer to leverage their excellence in pharmacovigilance and together create a better future with increased collaboration across the healthcare ecosystem.”

Read More: The Top 5 “Recipes” That Give AI Projects a Higher Likelihood of Success

Genpact’s PVAI solution, which incorporates the Genpact Cora PharmacoVigilance software product, has the ability to identify and analyze patient safety data by facilitating a faster detection of trends within large data volumes. As a result, PVAI has the potential to uncover new drug-related side effects earlier, and therefore could potentially improve pharmaceutical companies’ ability to better ensure patient safety.

“With Genpact, we have found a partner whose innovative capabilities in the area of applying advanced AI and machine learning technologies to pharmacovigilance provide us with an opportunity to further increase the efficiency of our pharmacovigilance operating model and case processing, while maintaining our high quality and compliance standards,” said Michael D. Levy, Global Head of Pharmacovigilance for Pharmaceuticals and Consumer Health, Bayer AG. “We believe that Genpact’s PVAI solution can help us to continue strengthening our position as a leading pharmacovigilance organization, focusing on patient safety.”

Read More:  Fluor Uses IBM Watson to Deliver Predictive Analytics Capability for Megaprojects

Genpact has won recent competitive proof of concept trials conducted by large pharmaceutical companies, in which the Genpact PVAI solution demonstrated industry-leading performance in automated extraction of adverse event data from source documents, as well as superior machine learning capacity over other solutions. Bayer, as an early adopter, is among the first companies going live with Genpact’s AI-based Case Management module of the PVAI solution suite.

Genpact has been investing heavily in combining its deep process and domain expertise with AI-led digital capabilities to further build its end-to-end pharmacovigilance solution, most recently with the addition of Commonwealth Informatics to the Genpact PVAI team. Interested parties can learn more about how we expect Genpact’s suite of PVAI capabilities to help transform pharmacovigilance operations.

Read More: The AI Gold Rush: How to Make Money off AI and Machine Learning!